Neurogene (NGNE) Total Debt (2013)

Neurogene's (NGNE) quarterly Total Debt came in at $2.3 million in Q4 2013.

Neurogene (NGNE) Total Debt (2013) Analysis & Trends

Neurogene (NGNE) has 1 years of Total Debt data on file, last reported at $2.3 million in Q4 2013.

Quarterly Total Debt changed N/A year-over-year to $2.3 million in Q4 2013, while the trailing twelve-month figure through Dec 2013 was $2.3 million (changed N/A YoY) and the FY2013 annual result came in at $2.3 million, changed N/A from the prior year.
Total Debt steadied at $2.3 million in Q4 2013.
In the past five years, Total Debt ranged from a high of $2.3 million in Q4 2013 to a low of $2.3 million in Q4 2013.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	1.07 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	9.34 Bn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	546.77 Mn
10	Neurogene	815.03 Mn	815.03 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2013	2.29 Mn